Based on the latest clinical progress, the bispecific antibody platform of EXCYTE, which combins two unique monoclonal antibody into one, has been tested as a novel molecule to realize the activity effect of 1+1>2.
Based on the latest clinical progress, the bispecific antibody platform of EXCYTE, which combins two unique monoclonal antibody into one, has been tested as a novel molecule to realize the activity effect of 1+1>2.